London – A new study aimed at advancing research in lung cancer has been announced by Oncogene Cancer Research, in collaboration with genetic health and biopharmaceutical company 23andMe Holding Co. and 20 lung cancer advocacy organizations. The Lung Cancer Genetics Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in order to improve detection, risk reduction, and care for those affected by lung cancer.
“Through this collaborative effort, we hope to understand how genetic factors play a role in lung cancer and ultimately improve outcomes and personalize care for millions of patients diagnosed with lung cancer each year,” said Yvonne Diaz, Co-Founder and Chair of Oncogene Cancer Research.
The study is funded by Troper Wojcicki Philanthropies and will include de-identified data that will be accessible to approved researchers at no cost. The goal is to recruit 10,000 individuals who have been diagnosed with lung cancer, with no restrictions on type, stage, gender, smoking status, or biomarkers.
Despite recent developments in treatment and targeted therapies, lung cancer remains the number one cause of cancer deaths in the United States. In 2020, it took more lives than breast, colorectal, and prostate cancers combined. The study hopes to address this critical area of unmet need and improve the long-term survival rate for those with lung cancer.
“The launch of the Lung Cancer Genetics Study fills an unmet need for a comprehensive database that bridges the gap between genetic, clinical, and patient-reported data,” said Anne Wojcicki, Co-Founder and CEO of 23andMe.
The study is supported by 20 lung cancer advocacy organizations and aims to reflect the diversity of those impacted by the disease. Participants must be 18 years or older, living in the United States, and have been diagnosed with lung cancer. The study is currently recruiting and participants can receive the 23andMe kits at no cost.
For more information on the study and how to participate, visit here.
About Oncogene Cancer Research:
Oncogene Cancer Research is a cancer patient and family-led charity funding and advocating for medical research into oncogene-driven cancers, such as EGFR and ALK. Their mission is to increase the life expectancy for people with these cancers through advocating for improvements and fundraising for medical research.
About 23andMe:
23andMe is a genetics-led consumer healthcare and biopharmaceutical company focused on empowering a healthier future. For more information, please visit www.23andMe.com.
Media contact:
admin@oncogeneresearch.org
